BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ozyigit G, Hurmuz P, Yuce D, Akyol F. Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer. World J Clin Oncol 2019; 10(8): 283-292 [PMID: 31528544 DOI: 10.5306/wjco.v10.i8.283]
URL: https://www.wjgnet.com/2218-4333/full/v10/i8/283.htm
Number Citing Articles
Monique Barnard, Elahe A. Mostaghel, Richard J. Auchus, Karl-Heinz Storbeck. The role of adrenal derived androgens in castration resistant prostate cancerThe Journal of Steroid Biochemistry and Molecular Biology 2020; 197: 105506 doi: 10.1016/j.jsbmb.2019.105506
Juan Morote. The importance of appropriate castrate level measurements of serum testosterone in prostate cancer patientsRadiotherapy and Oncology 2022; 169: 150 doi: 10.1016/j.radonc.2022.01.028
Almudena Zapatero, Ana Álvarez, Araceli Guerrero, Xavier Maldonado, Carmen González San Segundo, María A. Cabeza, Carmen Martín de Vidales, Josep M. Solé, Agustí Pedro Olivé, Francesc Casas, Ana Boladeras, María L. Vázquez de la Torre, Susana Vara, Felipe.A. Calvo. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trialRadiotherapy and Oncology 2021; 160: 115 doi: 10.1016/j.radonc.2021.04.018
Adriana Aguilar, Jacques Planas, Enrique Trilla, Juan Morote. Methods for Evaluating the Efficacy of Medical Castration: A Systematic ReviewCancers 2023; 15(13): 3479 doi: 10.3390/cancers15133479
Nardana Bazybek, Yi Wei, Guanghui Ma. Advances in encapsulating gonadotropin-releasing hormone agonists for controlled release: a reviewJournal of Microencapsulation 2022; 39(5): 452 doi: 10.1080/02652048.2022.2100934